NEW YORK (GenomeWeb News) – SynapDx today announced the completion of a Series A1 financing round that brought in $6 million to support a clinical study in support of the company's test for autism spectrum disorders.

Funds from this round of financing came from North Bridge Venture Partners and General Catalyst Partners.

Southborough, Mass.-based SynapDx is developing a blood-based test that measures RNA expression to differentiate children who have a higher risk for ASDs from those who don't. Its test aims to identify children with ASD by the age of 36 months.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.